Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Analyst: Ford’s Stock Could Double
Analyst: Ford’s Stock Could Double
There’s no doubt that the Ford Motor Co. has been beset by troubles of late, but at least one market expert thinks Ford shares are a good buy and could double in price within the foreseeable future.
James K. Glassman, a regular columnist with Kiplinger’s magazine and senior fellow at the American Enterprise Institute, points out that Ford lost more than $7 billion in the 9-month period that ended last Sept. 30. The company is burdened by high costs, and sales fell 8 percent last year.
[At the beginning of this year, a share of Ford stock was selling for only $7.50, down from over $25 during the late 1990s.
Story continues below...
Glassman believes the low stock price presents an opportunity. "Ford’s market capitalization is just $15 billion, while its sales are $166 billion,” Glassman writes in Kiplinger’s.
"In other words, a dollar invested in Ford stock buys more than $10 worth of Ford revenues. A stock is usually considered a bargain if a dollar of investment buys a dollar of revenues.”
Similarly, Ford’s cash outpaces its market cap, and a dollar invested in the stock buys about $1.50 of Ford cash.
Glassman notes that Alan Mulally, a former Boeing executive, was brought in to run Ford. If Mulally can boost the company’s earnings to just $2 a share — still far below the late 1990s level — then even at a modest price-earnings ratio of 8, "the stock would double,” according to Glassman.
[Editor's Note: 5 Super-Safe Cash Investments — Beat Stocks by 500%]
Glassman’s tempered optimism about Ford relies on what he calls "faith-based investing,” which involves faith that certain companies have brands and histories that are so strong, they have a good chance of thriving when redirected.
He cites several examples: IBM stock rose from $21 to a high of $139 after Louis V. Gerstner Jr. was brought in to run the company; Apple stock soared after Steve Jobs returned to the company, rising from less than $4 a share to its recent level of $95; and Kmart — now called Sears Holdings after buying Sears — rose from less than $20 in 2002, before Edward Lampert arrived, to $178 by this past Jan. 16.
© NewsMax 2007. All rights reserved.
Editor's Notes:
Repost from ZIP512003 on Yahoo Board
Your question is a good one, though... IF we get "injunction" AND EU approval, what will happen?
First of all, what are the chances of each?
Injunction has nearly ZERO chance of happening.. why? Iplex™ has ORPHAN status with FDA... that means that it cannot be injuncted without a full YEAR advanced notice! (see Insmed's response to TRCA's injunction request).
Secondly, there is EVERY indication that Iplex™ WILL be approved by EMEA, as they are getting help through the process... EMEA helping Insmed
http://messages.finance.yahoo.com/Stocks...
So, the "hidden question" in your post is.. "what should I do about it"? IF you believe BOTH 1 AND 2 of the above, AND are not concerned with momentary fluctuations in PPS, buy 1/3 of a position here, then another 1/3 prior to 2/16, (the date of Wilken's decision), and the other 1/3 afterwards...BUT, IF you believe #1 IS likely to occur, (injunction), then you should hold off buying until after 2/16...
What are the dangers to each strategy? For strategy #1, there is a danger that some other "bad news" (in addition to the injunction), will happen between now and then, which would make your shares go down in value...
For strategy #2 the danger is that GOOD news will come prior to Feb 16, (settlement, buyout, compulsory license, etc.). In that case, the danger would be that you "can't sell from an empty wagon"... AND that the share price will go UP too fast to get onboard,
As you can see, there are no "easy" decisions here... IF you buy now, there are risks, (although small, imo), and IF you wait until after Feb 16th there are risks of missing a big gain, (more likely, imo).
NO stock comes without risks... NONE! The seasoned investor realizes that, and makes decisions based on all known risks, AND all known rewards. Investing, (or even "trading"), is NOT easy, and NOT for everyone...
GLTY!
Tobin Smith Recommendation
I think the reason he did this is INSM does not have the 10 banger rise he was looking for in his time frame. Most of his legacy stocks fall into this catagory,1 to 3 years. I also don't think he understands the whole picture with INSM.Most people realize it will take time.
Im gona hold
Hope I wont regret it.
Tobin Smith Recommendation is to Close the Position
Insmed (INSM): This niche biotech company is a hard one to figure. The news on Italy's request to make Iplex available to its doctors as an experimental treatment for Lou Gehrig's disease sounds great, but is very limited. The successful patent infringement lawsuit involving the same drug -- approved in the U.S. for children with a certain type of short stature disorder -- by competitors Genentech (DNA) and Tercica (TRCA) takes a lot of economics out of the stock as well.
If you were to hold Insmed for the long-term, and I mean extremely long-term, I think it has a 50/50 chance of getting into the market with drugs for insulin resistance, multiple sclerosis (MS) and HIV -- but the risk is the dilution in the stock as the firm raises more money to get to the finish line.
I've been patient as I can with INSM -- it's on our buy list as a legacy stock, which means a 3-5 year period -- but the recent news just does not make it the 10-bagger potential we are looking for. Time to sell and reinvest the cash.
Pinnacle Digest: Drug IPLEX Future and Movements Reviewed
via COMTEX
January 19, 2007
Jan 19, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Insmed Incorporated (NASDAQ: INSM) experienced an even day of trading Thursday accompanied by 1,601,759 shares traded. They have been requested by the Italian Ministry of Health, to make its drug, IPLEX(TM) (rhIGFI/rhIGFBP-3), available to physicians in Italy to treat patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. The request comes at the behest of ALS patients who have petitioned the Court. This spurred several Italian Court rulings ordering the Italian National Health System to provide the drug to these specific ALS patients. If this drug is accepted and more importantly is successful in Italy it may open up doors to be widely accepted. PinnacleDigest will be interested in these results, and continue to monitor Insmed Incorporated closely.
The pharmaceutical world is moving at a quick pace and only the most practical and in demand products will find their share of the market. PinnacleDigest believes companies within this sector are tied to the overall movement of the industry. We closely evaluate the healthcare sector and its sentiment before reviewing a company such as Insmed Incorporated. At PinnacleDigest we offer a unique approach to investing and are constantly striving to meet our client's needs. To continue with this review and find out exactly what we have to offer come explore us at www.pinnacledigest.com.
Acquisitions and product alliances of biotechnology companies have been rising drastically of late, and this is evident when reviewing the figures of last year. Bigger drug makers can foresee a future in which the environment and demand for drugs is a very positive one over the coming 25 years. These larger companies are buying up smaller companies, attempting to reach out to and control more of the market. The rate of these types of acquisitions and alliances rose an astonishing 32% in the year of 2006. This needs to be acknowledged and reviewed heading into the New Year.
In recapping 2006 and looking to the future, biotechnology companies raised $20 billion in partnership deals last year. That is up from $17 billion in 2005, according to Burrill. That increase doesn't seem overly amazing, but a growth of that size has not occurred in recent years.
Our members would remember our evaluation of Pfizer and its devastating losses following its discontinued development of the drug hailed to replace Lipitor. As expected the market overreacted to the news, dropping more than $3 over the 4th and 5th of December. Since then Pfizer's share value has stabilized increasing to $26.64 on the NYSE. They are poised to possibly lose up to half of their $51 billion in 2005 sales as a result of competition from generic drug makers. It is very simple to understand that as their patents expire, companies will be jumping at the chance to produce generic drugs and get a piece of the market. Pfizer has entered at least six research partnerships since November. As well as conducted two transactions which was disclosed and totaled a combined $450 million. These larger companies need to ensure growth, and if not from within it has to come in the form of smaller companies with drugs on the move.
Let's turn back to Insmed Inc. and learn about their drug in focus, IPLEX. The disease it combats is ALS which is a neurodegenerative disorder that causes progressive muscle weakness and loss of motor neurons. IGF-1 is a neurotrophic factor essential for normal development of the nervous system. In animal models and cell culture systems IGF-1 protects motor neurons and promotes muscle and nerve regeneration.
Let's hear from Geoffrey Allan, President and CEO of Insmed, following the announcement. "We are very pleased that the Italian ministry has approached us to help in treating this devastating disease." He went on to state that, "We greatly appreciate the fact that Cephalon has collaborated with us in this effort. We hope that data collected from this expanded access program will be useful for the further clinical development of IPLEX for this indication." PinnacleDigest will be monitoring this development and its future implications. To learn more about our acclaimed online investor based community, visit us at www.pinnacledigest.com.
To continue with this report as well as other related articles, please visit www.pinnacledigest.com for a complimentary membership. It should be stated that our membership requires no commitment to our service. If you would like to contact us please write to support@pinnacledigest.com.
NORTH40000
My 85 year old dad suffered for years with rheumatoid arthritis. The Capsaicin (Topical) was the only thing that helped with the pain. It burns like hell when you first use it but works wonders. Hope Capsaicin will work in humans with diabetes as well.
Ed
Interesting read about posible Diabetes breakthrough
http://www.canada.com/nationalpost/news/story.html?id=a042812e-492c-4f07-8245-8a598ab5d1bf&k=639...
Thanks smallinvestor
'read_this_n0w'
Could you or anyone else explain this in layman's terms?
Thanks
Article out - "Insmed should merge"
http://biz.yahoo.com/seekingalpha/061214/22399_id.html?.v=1
SeekingAlpha
Insmed Loses Patent Case to Tercica; Companies Should Merge
Thursday December 14, 2:23 am ET
Andrew Vaino submits: As I mentioned last week in the Daily Blog, the patent case between Insmed (NASDAQ: INSM - News) and Tercica (NASDAQ: TRCA - News) decided in Tercica's favor. A jury found that Insmed infringed on Tercica's patents and ordered them to pay $7.5M in damages.
As well, Insmed was ordered to pay Tercica a 15% royalty on sales of less than $100M and 20% on sales above $100M. Insmed hasn't filed any appeal. I'm very happy I had a stop order for $1.50, and got out with a slight profit. INSM is now trading at less than a dollar.
To recap, both Insmed and Tercica sell insulin-like growth factor-1 [IGF-1] for the treatment of growth deficiencies in children who don't respond to normal human growth hormone therapy. Tercica's drug, Increlex, is given twice a day by injection and Iplex, Insmed's drug, is given once a day. Iplex is cleverly delivered with a complementary binding protein to improve distribution in the body.
Of the two, I think Insmed has the better pipeline. In addition to Iplex to treat growth deficiency, Insmed completed Phase 2 studies looking at application of Iplex to diabetes (in particular extreme insulin resistance), as well as to patients receiving skin grafts. Insmed also has a Phase 1/2 clinical study underway to treat prostate cancer and has a potential treatment for complications arising from HIV. According to the FDA's website, Insmed is not currently pursuing any Phase 3 studies.
Tercica recently licensed Somatuline Autogel to treat patients with acromegaly (a disorder in which the pituitary gland produces too much growth hormone). A NDA had been filed, and Tercica should hear back late next year. This, like Increlex, won't have a huge market but, as I mentioned, that's ok for such a small company.
While Tercica is the stronger company right now, I think the small market size for its products won't provide for much increase in stock price and therefore I wouldn't buy. Indeed, TRCA is up less than 15% since the verdict: this is still preferable to the 50% haircut INSM has taken.
I think Insmed is now is a world of hurt. In a best case scenario sales for Iplex will not be great (likely less than $200M/yr), so losing 15-20% hurts. Also, manufacturing IGF-1 isn't easy or cheap. Last spring INSM took a plunge when their auditors said they weren't certain the company had the ability to continue as a going concern. This report was a bit premature in that it didn't take into account a secondary offering of stock (predicted the week before in the Weekly Newsletter!) into account.
Regardless, at the end of Q3 Insmed has ~$30M net current assets, very weak sales, and no new products on the horizon for years. With a stock price below ninety cents, financing options are limited.
I think Iplex is a better drug than Increlex. My take, as I mentioned previously, is the best thing is for these companies to merge. Given the bad blood between them this won't be easy (the two companies have been almost absurdly litigious) but right now I think Insmed has no choice. So, while I wouldn't buy INSM right now it's worth keeping an eye on. A merger or outright acquisition, which I predict, will send the stock up. It's just a question of finding the bottom.
As a follow-up to my post on Friday about Encysive (NASDAQ: ENCY - News), the spike it received on announcement they were resuming a Phase 2 study on TCB3711 has dissipated (even after a single 'thumbs up' from Cramer on Monday night). My highly speculative short position is still under water, but less worryingly so.
Email this page to a friend
DECENT POST FROM apenny4em FROM YAHOO BOARD
Insmed has this all under control (9 Ratings) 13-Dec-06 07:01 pm The bashers have had a few great days flooding the board with opinions on the dire position Insmed is in. I loved the one being peddled by the TRCA shareholders about the merger. I have news for you guys:
1) Your bashing doesn't have ANY effect on the share price. The 'newby' who you are persuading to sell his Insmed shares has never existed. I'm afraid that you've wasted your time.
2) There will be no merger between Insmed and Tercica. TRCA's fate is at the mercy of Ipsen. There is no future for Increlex. There is no fairy tale ending for you.
Insmed's position is as follows:
They know that their case will be successful on appeal, if not sooner. Have a look at Trial Doc 952 if you doubt this. The movement in the share price during the trial was enough to tell anybody with half a brain that Insmed has a winning case - the jury's verdict was just a blip. The parties with whom they have been negotiating also know this - believe it or not, they employ the best legal eagles. Which brings me to
This trial has had a NEGLIGIBLE effect on Insmed's financial position. Insmed has been planning a partnership for a long time - knowing that they would need more cash by mid-2007. Win or lose, the trial was never going to change that.
All of the foregoing is crystal clear to the judge. She knows a partnership will shortly be announced. She knows that Insmed is confident that they will win the case sooner or later. So the idea that she has delayed her decision on the injunction for two months in order to force a settlement is laughable (and the invention of the TRCA shareholders). Which begs the question -
Why the delay?
Apparantly she is going to back the jury's verdict.
Apparantly she is going to dismiss the IC allegation.
The IC hearing was on the 29th November. All she had to do after that was to decide on the (triple?) damages and future royalties or injunction. Why the two months?
Imo, she has DECIDED that Genetech have a case to answer on the Inequitable Conduct charge, and she needs the time -
1) to go through the evidence submitted by Insmed to ascertain that it is factual. See Trial Doc 1007 - it's pretty compelling stuff. See Trial Doc 1008 - it's Genetech's response, and it has guilt written all over it. Lots of 'it was never our intention' (as though that will get them off the hook).
2) to decide on Insmed's JMOL requests.
3) to decide on the reduced damages.
And once again, there CANNOT be an injunction -
1) The judge is well aware of the applicable Supreme Court ruling.
2) The judge is well aware that Increlex cannot fill the gap which would be left if Iplex was withdrawn. TRCA/Genetech's expert witness testified that if Increlex was administered at dosage equivalent to the optimal dosage of Iplex it would cause serious side effects to some patients.
3) It is common knowledge that dosage of Increlex at ANY level promotes cancer growth - not so important when children are the patients, but absolutlly crucial for the other indications which are currently the subject of clinical trials.
4) The Federal Government has made available $7.5m for the purchase of Iplex - THEY think that it is an important development.
I live in the UK, and I work during the day. Although the bashers' posts have no effect on the share price, it's still depressing to see a board full of them. Could I ask any longs who see any value in this post to keep it, and others like it, on the front page please?
Rate it:
apenny4em
--------------------------------------------------------------------------------
View Messages
Ignore User
Report Abuse
The best part from the article
``It's very low risk given that the interest of the public is at stake,'' Matthew Osborne, an analyst at Lazard Capital Markets in New York, said in a phone interview. ``There would likely be a backlash from physicians if this drug were removed.''
INSM mentioned on CNN
http://tinyurl.com/yadz77
Nice post zake1
I think now more than ever, INSM will have to put the PR machine in over drive to combat the TRCA spin that will happen.
Hope you have a nice Thanksgiving
ED
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=1...
What is really true is that after consulting with experts, they were advised that the '414 was invalid due to prior art, and because the '733, (the equivalent to the '414), was revoked in Europe. That is what is true!
You cannot infringe an "invalid" patent, willfully or otherwise!
NASDAQ to Host Industry Panel on the State of the Worlds AIDS Epidemic
via COMTEX
November 20, 2006
Panel to Take Place On Dec. 1st World AIDS Day From NASDAQ MarketSite Followed by a Closing Bell Ceremony
ADVISORY, Nov 20, 2006 (PrimeZone Media Network via COMTEX News Network) --
What: The NASDAQ Stock Market will host an industry panel
luncheon and discussion focused on new research in the
fight against Acquired Immunodeficiency Syndrome (AIDS).
The panel will include industry experts and executives
from NASDAQ-listed Biotechnology companies that will
cover an array of industry topics ranging from prevention
and viral resistance, to quality of life treatments.
Following the panel discussion, there will be a NASDAQ
Closing Bell Ceremony in honor of World AIDS Day with
our panel members and NASDAQ representatives.
Who: Moderator:
---------
-- Emilio A. Emini, Ph.D. Executive Vice President,
Vaccine Research and Development for Wyeth
Pharmaceuticals
Panelists:
---------
-- Geoff Allan, Chief Executive Officer, President and
Chief Executive Officer of Insmed Incorporated
(Nasdaq:INSM)
-- Paul J. Maddon, M.D., Ph.D., Founder, Chief Executive
Officer and Chief Science Officer, Progenics
Pharmaceuticals, Inc. (Nasdaq:PGNX)
-- Douglas A. Michels, President & Chief Executive
Officer at OraSure Technologies, Inc. (Nasdaq:OSUR)
-- George Usher, Chairman, President and Chief Executive
Officer, Polydex Pharmaceuticals Limited (Nasdaq:POLXF).
When: Friday, December 1st, 2006
1:30 p.m. - 2:00 p.m. - Lunch
2:00 p.m. - 3:30 p.m. - Panel Discussion
3:30 p.m. - 4:00 p.m. - NASDAQ Closing Bell
Reporters, analysts, and other industry members are welcome
to attend.
Where: NASDAQ MarketSite
4 Times Square (Corner of 43rd and Broadway)
New York, NY
Contacts: Silvia Davi
646-441-5014
silvia.davi@nasdaq.com
Jolene Libretto
646-441-5220
Jolene.libretto@nasdaq.com
RSVP: Interested parties should RSVP to Jolene Libretto
Jolene.libretto@nasdaq.com
Want a little more frustration? Post on Yahoo board claims Robert Baird upgraded TRCA as a buy and a $11.00 price target.
Former Amgen Manufacturing Executive Joins Insmed
Wednesday October 25, 5:05 pm ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ: INSM - News) announced today the addition of former Amgen executive Mr. Doug Farrar to Insmed's manufacturing operations in Boulder, Colorado as Vice-President of Insmed Therapeutic Proteins. While at Amgen from 1987 to 2005, Mr. Farrar had increasing operational and development responsibilities which included Process Development, Clinical Manufacturing and Commercial Manufacturing.
ADVERTISEMENT
With over 20 years of biotech industry operations experience including 18 years with Amgen, Mr. Farrar has produced over 20 products for use in Amgen clinical trials and has hosted numerous approval and periodic inspections for the FDA, Europeans and Health Canada. He has been involved in filing 11 Investigational New Drug (IND) Applications and 2 Biological License Applications (BLA). He has worked on dozens of products produced by recombinant DNA technology in microbial, yeast and mammalian cells systems. Doug's most recent role as Director of Manufacturing included responsibility for the successful transition of Amgen's very large scale Lake Center manufacturing plant from clinical to commercial production.
"I am excited to be joining the highly talented and innovative team at ITP and look forward to making significant contributions to the continued success of Insmed Inc.," said Mr. Farrar.
Insmed also announced that Mr. Dennis Lanfear has joined the Company as a Strategic Consultant focusing on production, commercialization and marketing areas. While at Amgen from 1986 to 1999, Mr. Lanfear founded the Process Development Department which became the preeminent organization of its type in BioPharma and a key strategic advantage for the company. During his tenure at Amgen, Mr. Lanfear directed efforts from post-discovery to Phase III for several development programs including wound healing, growth factors and neurotrophins. From 1986 to 1990, he managed Amgen's corporate product development relationship with SmithKlineBeecham. From 1990 to 1999, he managed and had direct budgetary responsibility for the $135MM development partnership with Regeneron Pharmaceuticals. He was also named vice president of market development where he defined long term competitive and reimbursement strategies for Epogen(TM), a multibillion dollar drug.
Mr. Lanfear is President of Lanfear Capital Advisors, focusing on investments in therapeutic product and device companies. He is also a Director of Anthera Pharmaceuticals, a clinical stage drug development company.
"The years of broad protein experience that Doug and Denny bring to Insmed Therapeutic Proteins will significantly enhance our Iplex(TM) commercialization capabilities," said Geoffrey Allan, President and Chief Executive Officer of Insmed.
Merck diabetes drug wins federal OK
By ANDREW BRIDGES, Associated Press Writer 36 minutes ago
WASHINGTON - Diabetics gained a new way of controlling their blood sugar levels Tuesday with the federal approval of a novel pill for Type 2 diabetes, which affects about 20 million Americans.
The
Food and Drug Administration said it approved Januvia, which enhances the body's own ability to lower blood sugar levels, after clinical trials showing the new pill works just as well as older diabetes drugs, but with fewer side effects like weight gain. The drug is made by Merck and Co. Inc.
Merck is expected to charge $4.86 for the once-daily tablet, a price tag that may limit its use. Older diabetes drugs can cost 50 cents a day.
Januvia, also known as sitagliptin phosphate, works with a one-two punch: It increases levels of a hormone that triggers the pancreas to produce more insulin to process blood sugar while simultaneously signaling the liver to quit making glucose. The pill does that by blocking production of an enzyme, called DPP-4, that normally inactivates that hormone.
Januvia is unlike any other oral drug for treating Type 2 diabetes. However, Novartis AG hopes to win FDA approval for a similar drug later this year.
In Type 2 diabetes, patients either don't produce enough insulin or cells in the body ignore it. Insulin is needed to process sugar. Without it, blood sugar levels soar.
The FDA approved Januvia for use in addition to diet and exercise to improve blood sugar levels in patients with Type 2 diabetes, alone or in combination with other commonly prescribed drugs.
"For the millions of Americans with Type 2 diabetes, who continue to have inadequate blood sugar control, the approval of Januvia marks an important advance in the fight against diabetes," said Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research. "We now have another new option that treats the disease in an entirely new way that can be added to existing treatment regimens to help patients gain more control over their blood sugar levels."
American Diabetes Association guidelines suggest diabetics cut their levels of an averaged measure of blood sugar levels, called A1c, to less than 7 percent. Many, if not most, diabetics exceed that threshold. Helping them drop below it could reduce their risk of serious complications, like kidney failure and amputations, the diabetes group says.
At a diabetes conference in June, Merck said Januvia lowered blood sugar levels by 0.67 percent in a yearlong trial, or just as much as another, older drug, glipizide. Roughly two-thirds of patients reached the ADA's 7 percent goal.
Most importantly, Merck said the Januvia patients also lost weight and experienced fewer episodes of exceedingly low blood sugar than those on glipizide, a member of the sulfonylurea class of drugs. Excess weight is a common problem in Type 2 patients.
The most common side effects of Januvia in clinical studies were upper respiratory tract infection, sore throat and diarrhea, the FDA said.
Analysts have predicted Januvia sales could reach $1 billion in 2009 for Whitehouse Station, N.J.-based Merck.
Merck hopes to win FDA approval in late March for another pill, called MK-0431, that combines Januvia and the diabetes drug metformin.
"There is a huge need for additional therapeutic options in this marketplace," said Jay Galeota, who manages Merck's global diabetes drug business.
More than 230 million people worldwide have diabetes, up from just 30 million in 1985, according to the International Diabetes Federation. Diabetes is expected to affect 350 million people by 2025.
___
According to port10 on yahoo board
""Judge Chen denied INSM's motion to exclude Backman #2 and #3 reports"".
From yahoo message board about motion
What the hell are you jabbering about?
The motion has nothing to do with a trial delay.
The motion was for a reconsideration of the Court's ruling in June that cleared up pre-trial memoranda. Simply put, the Court ruled in June that TRCA could go ahead and make a case for infringement of the 414 patent.
What INSM just put before the Court a couple days ago is::: they asked the Court to RECONSIDER its June opinion on the 414 patent decision.
And the Court agreed to reconsider it!!
Moreover, TRCA has 2 WEEKS from the 29th of September to file an objection.
Then INSM has 1 week from that date to object to TRCA'a objection.
Then the Court, once again, will decide if any part of the 414 patent was infringed.
Essentially, the Court has granted INSM a SECOND SHOT at getting the 414 patent infringement thrown out BEFORE the trial.
And for those of you who honestly expected the trial to begin in November, you had to be crazy to begin with. I filed a custody/parenting time/child support case against my ex a few years ago. The trial was scheduled 3 1/2 months from the time I filed. It didnt take place until almost a year later.
Its all a cat and mouse game. Jockeying for position. Believe me, there are more motions to be filed. I dont expect the trial to happen until spring of 2007. In my opinion, of course.
In the meantime, we should have at least one, possibly two, more quarterlies --- showing INSM kicking the shit of TRCA in the sales department.
All in all, VERY GOOD NEWS.
This might help.....
http://biotech.seekingalpha.com/article/13701
Don't know.
Insmed to Present at the BioCentury NewsMakers in the Biotech Industry Conference
via COMTEX
September 6, 2006
GLEN ALLEN, Va., Sep 06, 2006 (BUSINESS WIRE) --
Insmed Incorporated (NASDAQ: INSM) today announced that Philip J. Young, Chief Business Officer of Insmed, will present a corporate overview on Thursday, September 7, at 3:30 PM ET during the BioCentury NewsMakers in the Biotech Industry Conference taking place in New York. Investors may access a live audio webcast of the presentation via www.corporate-ir.net/ireye/conflobby.zhtml?ticker=INSM&item_id=1376375
About Insmed
Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit http://www.insmed.com.
Press Release Source: Solar EnerTech Corp.
Solar EnerTech Corp. Acclaims Passing of California Million Solar Roofs Bill SB1
Monday August 28, 9:00 am ET
MENLO PARK, CA--(MARKET WIRE)--Aug 28, 2006 -- Solar EnerTech Corp. (OTC BB:SOEN.OB - News) (the Company) will celebrate this week with the news that California's Million Solar Roofs bill, SB1 authored by Senator Kevin Murray, has finally passed on the Senate Floor by a vote of 36 to 4, and that the solar industry has at last gained bipartisan support for the nation's largest and most comprehensive solar program in the United States.
The bill was signed into law by Governor Schwarzenegger at a ceremony held at the new solar powered CalTrans building in downtown Los Angeles last week.
Throughout the past months after the original Million Solar Roofs bill was defeated by legislature, Solar EnerTech Corp., a California-based company, kept busy building its solar cell production plant in Shanghai, with the firm belief that the bill, or a similar act would someday become law and that the Company would become a supplier for the million solar roofs in its home state.
That day finally came last Tuesday. The new legislation dovetails with the existing Solar Initiative program established by the California Public Utilities Commission in January and moves the State rapidly towards the goal of building a million solar roofs within the next ten years. The primary components of the bill allow for increasing the cap on net metering thereby allowing solar customers to get credits on their electric bill for excess power generated by their personal solar system. SB1 increases the cap from 0.5% of a utility's total load to 2.5% enabling approximately 500,000 new solar system owners access to the net metering program.
Solar panels become a mandated standard option for all new homebuyers, thus empowering new home buyers the choice to add solar panels during new home construction. The bill also directs the California Energy Commission to asses and determine if and when solar power should be mandated on new construction as a standard, non-optional feature.
The law also requires that the state's municipal utilities create a solar rebate program, totaling $800 million in rebate funds to drive municipal utility ratepayers toward solar power and further directs the California State Licensing Board to review current licensing requirements for solar installers in order to determine if they have been adequately trained to install the large numbers of solar roofs expected to be purchased as a result of this program.
The overall effect of the law which is scheduled to come into effect January 1, 2007 is simply stated as having created the largest solar program in the nation and is aiming to build 3,000 MW of solar power -- the equivalent of 6 large power plants -- on homes, businesses, farms, and schools throughout the state.
Solar EnerTech developed its business model and soon-to-be-operational manufacturing facilities in Shanghai founded on the overall growth of the industry with the knowledge that many influential individuals and legislators both in the United States and abroad have shown unyielding commitment to alternative energy sources that have resulted in a number of highly effective programs and initiatives becoming enacted in a relatively short period of time. As a natural result of the increased demands brought about by these new acts, solar cell production supply will become the key for a successful outcome for manufacturers, integrators and consumers alike.
In China, with its sustained annual growth of 10% for more than 20 years and its relatively inexpensive labor and rich natural resources, the Company identified an extraordinary opportunity for a foreign renewable energy company to locate its manufacturing facility there, and Solar Enertech wasted no time grasping this opportunity. Leo S. Young, founder and CEO of the company, was a senior member of a California trade mission to the country last November and along with the participation of Governor Schwarzenegger managed to organize an Energy Round Table in Beijing, at which Schwarzenegger, key business leaders and Chinese high officials met for a series of discussions. During the round table, policies for renewable energy by both governments were discussed, favorable incentive packages were outlined, and a mechanism for communication and cooperation between California and China was established.
Less than two months later, China inaugurated its Renewable Energy Act (in January 2006), and Solar Enertech launched construction of its solar cell manufacturing plant in Shanghai beginning in February. As of today, the Company's infrastructure and production facility are on schedule to begin producing solar cells in late November at the anniversary of the Energy Round Table in Beijing.
About Solar EnerTech Corp. (OTC BB:SOEN.OB - News)
Solar EnerTech is a photovoltaic (PV) solar energy cell manufacturing enterprise based in Shanghai, China where the Company is establishing a sophisticated 42,000 square foot manufacturing and research facility in Shanghai's Jinqiao Modern Science and Technology Park. Solar EnerTech plans to invest in PV cell research to develop higher efficiency cells and put the results of that research to use immediately in its manufacturing processes. Led by one of the industry's top scientists, the Company's R&D program will work to bring Solar EnerTech to the forefront of advanced solar technology research and production. The Company has also established a marketing, purchasing and distribution arm in Northern California's Silicon Valley.
Forward-Looking Statements
Except for statements of historical fact, the information presented herein may contain forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which Solar EnerTech Corp. has little or no control.
On Behalf of the Board
Solar EnerTech Corp.
Leo Shi Young, President
Contact:
Investor Relations Contact:
Boundary Point Investor Relations Inc.
1-866-378-7372
http://www.solarenertech.com
Vaino’s Biotech Corner
Week Ending July 14, 2006
Vaino’s Biotech Corner: INSM and TRCA – Fighting Like Two-Year Olds
Even with the VIX finally moving again, biotech stocks have been pretty quiet. The biggest biotech story of the week, for me at least, was announcement on Wednesday that a patent dispute between Insmed (INSM) and Tercica (TRCA) would go to trial. I have written about these stocks before, and sold off TRCA in June’s market plunge. I still liked INSM so I kept it.
Both these companies have received FDA approval to sell insulin-like growth factor-1 (IGF) for the treatment of growth deficiencies in children. Tercica’s drug, Increlex, is given twice a day by injection and Iplex, Insmed’s drug, is given once a day. And note that Iplex is cleverly delivered with a complementary binding protein to improve distribution in the body.
Tercica claims that Insmed is using their patented technology to produce their drug. To read the headlines from the Tercica press release, it sounded like the court had already ruled that Insmed is infringing on their patent. However, all the court actually did was to deny Insmed’s request for summary judgement. That is, Insmed wanted the court to rule there was no evidence to support Tercica’s assertion. Courts typically only grant summary judgment if there is no evidence to support claims. Since Tercica had evidence to support its claim, the court had no choice but to proceed to trial. Only at trial can the validity of the evidence be determined. The trial is set to begin November 6.
In essence, Insmed will be seeking to establish that the patent issued to Tercica is invalid based on prior art. It’s now up to the court to decide if this is true or not.
A different court case in which Tercica sued Insmed for false advertising was thrown out last month. These guys just don’t seem to play well together.
While I don’t believe this is a killing blow for Insmed, it did knock the stock price down 33% from where it was last week, to under $1.30. Tercica saw a modest jump on the day of the announcement, but it’s actually down for the week.
I think Iplex is the better drug. A study published in May 2006 in Expert Opinion on Biological Therapy found protein-bound IGF had a superior safety profile as compared to the unbound. Also, Iplex is administered once a day compared to twice a day for Increlex. Ask yourself, would you rather get one needle a day or two needles a day? Now go ask a five year old. I’m pretty certain I know the answer.
This is a good drug, but it’s a niche product, and there likely isn’t room for two competitors anyway. TRCA is a one shot wonder (they licensed the drug from Genentech) while INSM has other ongoing clinical trials. Even if Tercica prevails in the trial, which is not certain, they’re still left with an inferior product: Insmed has patented delivery with the binding protein.
Neither INSM nor TRCA have strong balance sheets (TRCA’s is marginally better) and court cases are expensive and risky. My take, and this is definitely not for the faint of heart, is that if the trial goes well for Tercica it would still be worth their while to enter into an agreement with Insmed. The trial could well drag on for years, and Insmed will continue selling Iplex. If Tercica were to prevail and compel them to stop, the publicity of forcing little kids to have to take two needles a day instead of one likely isn’t going to be good. I might get my head handed to me, but I’m seriously thinking of buying more INSM.
For your information Avalon Pharmaceuticals'
http://www.wrhambrecht.com/research/biotech/avrx.html
08.10.06
avrx: EARLY SIGNS OF BIOLOGIC ACTIVITY OBSERVED IN PHASE I AVN944 TRIAL; CLINICAL DATA ON-TRACK FOR Q4:06
Avalon Pharmaceuticals' reported Q2 loss was roughly in line with expectations, but overall a non-event for AVRX shares. We believe the main driver to the story remains the company's lead product, AVN944, which we estimate could achieve peak sales of $500M and is 100% owned by Avalon. Specifically, enrollment in the Phase I trial is on track to yield efficacy data in Q4 that we expect will likely show signs of activity across a variety of hematological cancers. On the company's conference call Wednesday morning, management indicated that early signs of biological activity were observed across a variety of biomarkers. We believe the Phase I data will support the initiation of Phase II trials in hematological malignancies by YE:06 and solid tumors in H1:07. Given that AVRX shares are currently trading slightly above its cash position, we view current levels as reflecting a compelling risk/reward. We are reiterating our Buy rating and $13 YE:06 price target on AVRX shares. Full Report - PDF
Posted by: nanookknows
In reply to: ED20332 who wrote msg# 2853
Date:8/11/2006 11:09:21 AM
Post #of 2858
This technology cannot, in any way, shape or form, be used for carry-on baggage. The technology involves making the substances (hair gels, etc) radioactive for a short period of time and then analyzing the decay spectrum.
20 years ago, in an earlier part of my career, I visited Westinghouse in PA. They had a prototype of this technology (known as neutron activation analysis) and it was already in beta testing at 3 airports at that time. The upside is there for checked baggage and cargo, but it is complicated and it takes people a bit smarter than the average TSA screener.
You hit the nail right on the head!! Why the hell do you need to take toothpast, shaving cream, soap, ect. on a a carry on? Are you going to take a bath of shower on the plane?
We need to copy the security that is used at middle eastern airlines.
No carry on stuff. Period!!!!
This country has to get real about this !
It is in the orange county register. If the link does not open, go to www.orangecountyregister.com and look for "air safety made in o.c" on the front page
http://ocregister.com/ocregister/homepage/abox/article_1240664.php
riday, August 11, 2006
Air safety made in O.C.?
By JOHN GITTELSOHN
The Orange County Register
A small Irvine company may have the technology that would allow passengers to bring their hair gels and beverages aboard planes again without compromising safety.
HiEnergy Technologies developed a chemical detection system that some experts say could help foil plots to blow up planes such as the one exposed in Britain this week. For years, though, the company has struggled to sell the system to airport authorities.
“I think their technology is revolutionary and we need it,” said Charles Slepian, founder of the Foreseeable Risk Analysis Center in New York.
Current airport screening devices, such as X-ray machines, cannot see chemicals inside sealed packages. That's why airlines banned passengers from bringing liquids on planes.
“What happened today tells us we have to revisit baggage screening,” said Roger Spillmann, chief executive officer of the 20-employee company.
HiEnergy's devices can see into packages by shooting neutrons which bounce back as gamma rays that paint a distinct signature for each chemical, enabling screeners to spot nitroglycerine, plastic explosives, drugs such as cocaine or plain water.
“Each element has its own energy so we can pick up chemical formulas,” Spillmann said. “We also can tell you the components are there to mix explosives.”
Currently, only the Southeastern Pennsylvania Transportation Authority, a commuter rail operator, has contracted to use HiEnergy's “Atometer” explosive detection system. HiEnergy has also won research contracts with the U.S. military for products to search for landmines, unexploded ordnance and improvised explosive devices.
Spillmann said the Transportation Security Administration, which oversees airport security, is reluctant to deal with a company as small as HiEnergy.
Nico Melendez, a Los Angeles spokesman for the Transportation Security Administration, said he is unfamiliar with HiEnergy but his agency welcomes new ideas.
“Obviously, we constantly work with industry to improve and develop new technology,” Melendez said.
Another concern is that chemical screenings would slow the boarding process. Spillmann said the TSA wants to process 10 packages a minute but his company's machines can read only about two or three packages a minute. He said it would take $1 million and one year for HiEnergy to build a usable prototype.
Slepian, the risk analyst and a frequent critic of the TSA, conceded that HiEnergy's technology is too slow to screen all baggage but might work as a secondary process.
“The government is right when they say they're a little company.” Slepian said. “But the government's job is to make them bigger when they can save lives.”
C
While we are waiting.....
Check out this company HIET.OB. This mornings article.
Air safety made in O.C.?
By JOHN GITTELSOHN
The Orange County Register
A small Irvine company may have the technology that would allow passengers to bring their hair gels and beverages aboard planes again without compromising safety.
HiEnergy Technologies developed a chemical detection system that some experts say could help foil plots to blow up planes such as the one exposed in Britain this week. For years, though, the company has struggled to sell the system to airport authorities.
“I think their technology is revolutionary and we need it,” said Charles Slepian, founder of the Foreseeable Risk Analysis Center in New York.
Current airport screening devices, such as X-ray machines, cannot see chemicals inside sealed packages. That's why airlines banned passengers from bringing liquids on planes.
“What happened today tells us we have to revisit baggage screening,” said Roger Spillmann, chief executive officer of the 20-employee company.
HiEnergy's devices can see into packages by shooting neutrons which bounce back as gamma rays that paint a distinct signature for each chemical, enabling screeners to spot nitroglycerine, plastic explosives, drugs such as cocaine or plain water.
“Each element has its own energy so we can pick up chemical formulas,” Spillmann said. “We also can tell you the components are there to mix explosives.”
Currently, only the Southeastern Pennsylvania Transportation Authority, a commuter rail operator, has contracted to use HiEnergy's “Atometer” explosive detection system. HiEnergy has also won research contracts with the U.S. military for products to search for landmines, unexploded ordnance and improvised explosive devices.
Spillmann said the Transportation Security Administration, which oversees airport security, is reluctant to deal with a company as small as HiEnergy.
Nico Melendez, a Los Angeles spokesman for the Transportation Security Administration, said he is unfamiliar with HiEnergy but his agency welcomes new ideas.
“Obviously, we constantly work with industry to improve and develop new technology,” Melendez said.
Another concern is that chemical screenings would slow the boarding process. Spillmann said the TSA wants to process 10 packages a minute but his company's machines can read only about two or three packages a minute. He said it would take $1 million and one year for HiEnergy to build a usable prototype.
Slepian, the risk analyst and a frequent critic of the TSA, conceded that HiEnergy's technology is too slow to screen all baggage but might work as a secondary process.
“The government is right when they say they're a little company.” Slepian said. “But the government's job is to make them bigger when they can save lives.”
- - - - -
View Replies »
Who give a Rat's ars about yahoo?
Just pack your bags and leave. Nothing but boiler room bashers and retards on it.Stay here or on Investor Village
Press Release Source: Insmed Incorporated
Insmed Inc. to Webcast 2006 Second Quarter Financial Results Conference Call, Tuesday, August 8, 2006 at 4:30 p.m. (ET)
Wednesday July 19, 4:12 pm ET
GLEN ALLEN, Va.--(BUSINESS WIRE)--July 19, 2006--Insmed (NASDAQ:INSM - News) announced today that it will release its 2006 second quarter financial results on Tuesday, August 8, 2006 after market close.
The Company will host a conference call on Tuesday, August 8 at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.
Interested investors can listen to the call over the internet from Insmed's investor relations website at www.insmed.com or by dialing 800-361-0912 (domestic) or 913-981-5559 (international).
A telephonic replay of the call will be available for one week at 888-203-1112 (domestic) or 719-457-0820 (international), passcode: 1703416. A web replay of the call will be available through the corporate website beginning at 6:00 p.m.
lets hope so
Thanks,
Ed
Interesting company with NEW oral insulin pill
www.oramedpharma.com ORMP.OB
Release Source: Oramed Pharmaceuticals, Inc.
Oramed Pharmaceuticals' Receives Strong Upgrade by Respected Research Firm
Thursday June 22, 11:58 am ET
JERUSALEM--(BUSINESS WIRE)--June 22, 2006--TRI-STATE Capital (TSC), has upgraded their equity rating on ORMP. This strong upgrade comes at a time when the company reported successful pre-clinical studies of their orally ingestible soft gel insulin capsule for the treatment of type 1 and 2 diabetes. According to the American Diabetes Association, roughly 20.8 million children and adults have diabetes. Of those who have the condition, approximately 28 percent take insulin to offset the defect.
TSC is noted for their work with, account executives, analysts, portfolio managers, institutions, venture capital investors, individual investors and the media. To view the entire independent research report, please click on the attached URL: http://www.otclive.com
About Oramed Pharmaceuticals
Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of type 1 and 2 diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For additional information, please visit their web site at: www.oramedpharma.com
----------------------------------------------------------------
Oral Insulin Pill Could Bring Relief to Millions
Tuesday June 20, 8:32 am ET
NEW YORK, June 20 /PRNewswire/ -- Researchers at Hadassah-University Hospital, located in Jerusalem, have been working on a new insulin pill that could mean big changes for diabetics. The renowned team of researchers from Oramed Pharmaceuticals, led by Dr. Miriam Kidron and Professor Hanoch Bar-On, has developed a breakthrough method of delivering insulin orally.
Diabetes is an imperfection in the body's insulin production and/or action. There are two kinds of diabetes, Type 1 and Type 2. Previously called juvenile-onset diabetes, Type 1 includes up to 10 percent of all cases. Type 2 diabetes, formerly called adult-onset diabetes, accounts for over 90 percent of all cases. According to the American Diabetes Association, roughly 20.8 million children and adults have diabetes, a number that equals about 7 percent of the population. Of those who have the condition, around 28 percent take insulin to offset the defect.
Currently, some of the Type 2 diabetics take medication to enhance their body's limited ability to produce insulin. In many cases, their body's ability to produce insulin deteriorates over time. Many of them may eventually need to inject insulin. A major difference between the medication available today and what Oramed's oral insulin is expected to do is that Oramed hopes to limit the further deterioration of the body's ability to produce insulin, minimizing the need to inject insulin in the future.
At some point, the insulin pill may be able to help Type 1 diabetics and, in some cases, may even be utilized instead of the injection. Over the last decade or so, cases of Type 2 diabetes have been on the rise, with medical experts seeing marked increases in the number of children with the condition. This is believed to coincide with the obesity epidemic, as Type 2 diabetes is often related to obesity and lack of physical activity.
Oramed Pharmaceuticals is a publicly held company (OTC Bulletin Board: ORMP - News) and has recently applied to conduct Phase One clinical trials.
Contact: Jacqueline Bodnar, JB@SyndicatedNews.us, (702) 338-3105
Rstor1 could Trca do this?
""'Given the above, I have to believe that they need to shut Insmed down, and would not look to settle, unless it was in the form of a merger.""""
Insmed: Court decision does not fully resolve all issues
Print | | Disable live quotes By Gabriel Madway
Last Update: 2:33 PM ET Jul 5, 2006
SAN FRANCISCO (MarketWatch) -- Insmed Inc. (INSM : insmed inc com new
News , chart, profile, more
Last: 1.43-0.11-7.14%
2:46pm 07/05/2006
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
INSM1.43, -0.11, -7.1%) said Wednesday that last Friday's court decision does not fully resolve all of the pending issues regarding any of the three patents at issue. Tercica Inc. (TRCA : tercica inc com
News , chart, profile, more
Last: 5.15-0.12-2.28%
2:46pm 07/05/2006
TRCA5.15, -0.12, -2.3%) said earlier Wednesday that the district court ruled that Insmed infringed on three patent claims related to its Iplex compound. Glen Allen, Va.-based Insmed said the remaining issues will be resolved at trial, and that the decision does not have any impact on its ability to continue to sell Iplex, a treatment for children with short stature associated with severe primary IGF-I deficiency.